However, the negative results published today in Nature Biotechnology on a groundbreaking trial in ALS deserve to be celebrated. The trial was conducted exclusively through PatientsLikeMe, the online medical social network that serves as a forum for patients in all disease areas to “share real-world health experiences.”
According to a very nice write-up in the Wall Street Journal, the trial was conceived and initiated by ALS patients who were part of the PatientsLikeMe ALS site:
Jamie Heywood, chairman and co-founder of PatientsLikeMe, said the idea for the new study came from patients. After the 2008 paper reporting lithium slowed down the disease in 16 ALS patients, some members of the site suggested posting their experiences with the drug in an online spreadsheet to figure out if it was working. PatientsLikeMe offered instead to run a more rigorous observational study with members of the network to increase chances of getting a valid result.The study included standardized symptom reporting from 596 patients (149 taking lithium and 447 matched controls). After 9 months, the patients taking lithium showed almost no difference in ALS symptoms compared to their controls, and preliminary (negative) results were released in late 2008. Although the trial was not randomized and not blinded – significant methodological issues, to be sure – it is still exciting for a number of reasons.
First, the study was conducted at an incredible rate of speed. Only 9 months elapsed between PatientsLikeMe deploying its tool to users and the release of topline results. In contrast, 2 more traditional, controlled clinical trials that were initiated to verify the first study’s results had not even managed to enroll their first patient during that time. In many cases like this – especially looking at new uses of established, generic drugs – private industry has little incentive to conduct an expensive trial. And academic researchers tend to move a pace that, while not quite glacial, is not as rapid as acutely-suffering patients would like.
(The only concern I have about speed is the time it took to get this paper published. Why was there a 2+ year gap between results and publication?)
Second, this trial represents one of the best uses of “off-label” patient experience that I know of. Many of the physicians I talk to struggle with off-label, patient-initiated treatment: they cannot support it, but it is difficult to argue with a patient when there is so little hard evidence. This trial represents an intelligent path towards tapping into and systematically organizing some of the thousands of individual off-label experiences and producing something clinically useful. As the authors state in the Nature paper:
Positive results from phase 1 and phase 2 trials can lead to changes in patient behavior, particularly when a drug is readily available. [...] The ongoing availability of a surveillance mechanism such as ours might help provide evidence to support or refute self-experimentation.Ironically, the fact that the trial found no benefit for lithium may have the most far-reaching benefit. A positive trial would have been open to criticism for its inability to compensate for placebo effect. These results run counter to expected placebo effect, lending strong support to the conclusion that it was thoughtfully designed and conducted. I hope this will be immense encouragement to others looking to take this method forward.
A lot has been written over the past 3-4 years about the enormous power of social media to change healthcare as we know it. In general, I have been skeptical of most of these claims, as most of them fail to plausibly explain the connection between "Lots of people on Facebook" and "Improved clinical outcomes". I applaud the patients and staff at PatientsLikeMe for finding a way to work together to break new ground in this area.
No comments:
Post a Comment